Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.
Canada approves second generic version of Ozempic
The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic authorized in the country.
Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview)
Novo Nordisk faces sustained margin compression due to intensifying price competition in the GLP-1 weight loss drug market. Gross profit margin has declined from over 84% to 80%, and profit margin from over 36% to 33%, with further declines expected. Direct-to-consumer programs and the competitive situation have eroded previously robust self-pay margins for NVO's Wegovy.
Health Canada approves first generic version of Novo Nordisk's Ozempic
Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made by Indian drugmaker Dr Reddy's Laboratories , its website showed on Tuesday.
Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?
Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novo Nordisk (NVO) closed at $38.52, indicating a -1.61% shift from the previous trading day.
Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
Novo Nordisk's oral GLP-1 drug met the main goal of a late-stage study in children and adolescents aged 10 to 17 years with type 2 diabetes, the drugmaker said on Thursday.
Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health
Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that "2025 was probably the single most exciting year in my entire journey." The catalyst: GLP-1 medicines. His claim deserves scrutiny because the investment and personal... Biotech Investor Alex Karnal: GLP-1 Drugs Signal 'Trillion-Dollar Revolution' in Public Health
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
